Actinic Keratoses and Cosmetic Work: Why the Rough Spot Matters More Than the Brown One, What Fluorouracil, Imiquimod, and Photodynamic Therapy Actually Do, When a Peel or Laser Counts as Treatment, and Why the Biopsy Comes Before the Resurfacing

The patient is 61, spent two decades sailing and playing tennis, and books a consultation for a laser to "clean up the sun damage" before a lower face and neck lift next spring. They point to brown spots on the cheeks and a few rough patches along the temples and the top of the forehead that they pick at in the shower. The med spa they visited first offered an intense pulsed light package for the brown spots and said the rough patches would "come off with the laser too." Nobody touched the rough patches, looked at them under magnification, or used the word keratosis.

That gap is common, and it is the subject of this piece. The brown spots are mostly a cosmetic issue. The rough patches are actinic keratoses, and they are the part of the sun damage that a dermatologist actually tracks. They respond to treatments that overlap with cosmetic resurfacing, which is useful, but the overlap also creates two predictable mistakes: treating them as purely cosmetic, and destroying a lesion that should have been biopsied first. What follows is how to avoid both, and how to time the medical treatment around facial surgery, injectables, and lip work.

What an actinic keratosis is, and why the rough spot matters more than the brown one

The short answer: an actinic keratosis is a patch of sun-damaged skin cells with abnormal growth, usually felt before it is seen, and it matters because it marks skin where squamous cell carcinoma is more likely to develop, even though most individual spots never become cancer.

Actinic keratoses (AKs, also called solar keratoses) appear on skin that has taken years of ultraviolet exposure: the face, the scalp in people with thinning hair, the ears, the backs of the hands and forearms, the upper chest, and the lower lip. They are typically a few millimeters across, pink, red, or skin-colored, and rough or scaly. Many people find them by touch first, running a finger across the forehead and feeling a gritty patch that is not visible in the mirror. They may come and go, scab, and return in the same spot. Some are thick and horn-like (hypertrophic AKs); some are flat and pigmented, which makes them easy to confuse with an ordinary sun spot.

They are extremely common in fair-skinned adults over 50, and the American Academy of Dermatology (AAD) notes that a person with one AK usually has more. That is the key idea: an AK is not a single bad spot but a visible marker of a whole area of damaged skin. Dermatologists call this field cancerization. The skin between the visible lesions carries the same ultraviolet-induced mutations, and new lesions keep surfacing from it for years.

The risk numbers are reassuring for any single lesion and less reassuring for the field. Estimates of the chance that one AK progresses to invasive squamous cell carcinoma (SCC) are low, generally well under 1 percent per lesion per year, and a meaningful share regress on their own. But a person with many AKs has many lesions, a field of damaged skin, and an elevated lifetime risk of SCC. Studies of SCC on sun-exposed skin have found that a large share arise in or right next to an existing AK. The practical result is that AKs are treated less because any one of them is dangerous and more because treating the field lowers the number of future skin cancers and makes real cancers easier to spot.

Several groups carry much higher risk. Organ transplant recipients on long-term immunosuppression develop SCC at many times the rate of the general population, often aggressively, and dermatologists manage their AKs far more intensively. People on other immunosuppressive drugs, people with chronic lymphocytic leukemia, and people with a prior SCC also fall into higher-risk groups. The piece on cosmetic surgery with autoimmune disease covers the healing side of immunosuppression; the skin cancer side is a separate reason to have a dermatologist involved.

This is why the rough patch matters more than the brown one. The flat brown spots on the patient's cheeks were solar lentigines, which are harmless and respond well to the approaches in the piece on lasers for sun spots and pigmentation. The rough patches were the part of the face that needed a diagnosis. There is one important exception on the brown side as well: lentigo maligna, an early form of melanoma, can look like an ordinary sun spot on the cheek of an older adult. A brown spot that is larger, darker, irregular, or changing should be examined, and sometimes biopsied, before anyone treats it with light.

The treatment menu: freezing single spots versus treating the whole field

The short answer: isolated AKs are usually frozen with liquid nitrogen, while areas with many AKs are usually treated with a field therapy such as fluorouracil cream, imiquimod, tirbanibulin, or photodynamic therapy, all of which cause a planned period of redness and crusting.

The AAD published formal guidelines of care for AK management in 2021. They strongly recommend ultraviolet protection, and they recommend four main treatments: cryosurgery, topical 5-fluorouracil, topical imiquimod, and photodynamic therapy using aminolevulinic acid. Diclofenac gel received a weaker, conditional recommendation, and the guidelines also support combining cryosurgery with a field cream. A newer drug, tirbanibulin, was approved after the evidence review closed.

Cryosurgery. Liquid nitrogen sprayed on each visible lesion for a few seconds is the fastest office treatment. It blisters, crusts, and heals over one to two weeks. Clearance rates for individual lesions are good. Its limitations are cosmetic and strategic: it can leave white (hypopigmented) marks, particularly in medium and deeper skin tones, as covered in the piece on cosmetic procedures on deeper skin tones, and it treats only the lesions that can be seen, leaving the field untouched.

Topical 5-fluorouracil (5-FU). This chemotherapy cream, sold under several brand names, interferes with DNA synthesis in rapidly dividing abnormal cells. The classic course is the 5 percent cream applied twice daily for two to four weeks; lower-strength versions are applied once daily. The skin becomes red, raw, crusted, and sometimes eroded, peaking toward the end of the course and settling over a couple of weeks after stopping. The reaction is the treatment, not a side effect to avoid. Its evidence base is strong. In a Veterans Affairs randomized trial published in JAMA Dermatology in 2018, a single two-to-four-week course of 5 percent fluorouracil on the face and ears reduced the need for surgery on squamous cell carcinoma by roughly 75 percent in the first year compared with a placebo cream, with the effect fading after that. A short combination regimen pairing 5-FU with calcipotriol, a vitamin D analog, applied for four days, has also shown good clearance with a briefer reaction in published trials.

Two warnings belong on any 5-FU discussion. First, the drug's label warns that people with dihydropyrimidine dehydrogenase (DPD) deficiency, a rare enzyme problem, can have severe reactions even from the cream. Second, the FDA has warned that dogs who ingest even small amounts of topical fluorouracil, by licking a tube or the treated skin, can die. Households with pets should store the tube securely and keep the treated area away from them, which adds one more line to the practical advice in the piece on pets and plastic surgery recovery.

Imiquimod. This cream stimulates the immune system to attack abnormal cells. It is applied a few times a week or daily, depending on strength, over several weeks. The skin reaction resembles 5-FU but tends to be less predictable, and a minority of patients develop flu-like symptoms: fatigue, aches, low fever. Anyone with an autoimmune condition should mention it, because immune-stimulating creams have occasionally been linked to flares.

Tirbanibulin. Approved by the FDA in 2020 for AKs on the face and scalp, this ointment is applied once daily for five consecutive days. Its reactions are generally milder and shorter than with 5-FU, which makes it attractive for patients with a social calendar. The tradeoffs are cost, a smaller studied treatment area, and less long-term data than for the older creams.

Photodynamic therapy (PDT). A light-sensitizing solution of aminolevulinic acid is applied to the skin, left to absorb, and then activated with blue or red light, or in daylight PDT, with natural outdoor light under supervision. The treatment can be quite painful during illumination with lamp-based protocols; daylight versions hurt much less. Afterward the skin is red and peeling for about a week, and the patient must strictly avoid sunlight and bright indoor light for roughly 48 hours, because the treated skin remains photosensitive. PDT tends to produce smooth cosmetic results, and many patients like the side benefit of modest improvement in texture and fine lines. It is not the same as red light LED therapy sold for skin rejuvenation, which uses light without the drug and is not an AK treatment.

Diclofenac gel. A nonsteroidal anti-inflammatory gel applied twice daily for 60 to 90 days. It is gentle, but its clearance rates are lower, which is why the AAD rated it only conditionally.

For every field therapy, the downtime is real but predictable. A patient who knows that weeks two and three of a 5-FU course will look like a bad sunburn with crusting can plan around it. The piece on makeup after surgery explains why heavy camouflage on broken skin causes problems; the same logic applies here, and most dermatologists ask patients to keep products simple until the surface has closed.

Peels and lasers as field treatment, and the biopsy that should come first

The short answer: medium-depth chemical peels and ablative laser resurfacing can clear many AKs and may reduce future skin cancers, which makes them legitimate field treatments, but resurfacing destroys tissue without a diagnosis, so any suspicious lesion must be biopsied before it is lasered.

The overlap between cosmetic resurfacing and AK treatment is genuine. Ablative lasers, the carbon dioxide (CO2) and erbium lasers described in the piece on ablative versus non-ablative laser resurfacing, remove the outer layers of damaged skin and replace them with new epidermis grown from deeper, less damaged cells. A frequently cited 2006 study in the Archives of Dermatology followed patients after full-face resurfacing with CO2 laser or a medium-depth trichloroacetic acid (TCA) peel and found fewer new nonmelanoma skin cancers in treated skin than in untreated comparison areas. Older trials comparing a medium-depth peel (Jessner's solution followed by 35 percent TCA) with a 5-FU course found broadly similar AK clearance with less prolonged irritation. The deep phenol peel, reserved for severe photodamage in suitable candidates, resurfaces even more deeply.

Fractional lasers, which treat columns of skin and leave bridges of untreated tissue, are a weaker AK treatment on their own because they leave much of the field untouched. Their main medical use in this setting is to improve drug penetration: laser-assisted PDT, in which a fractional laser treats the skin before the photosensitizer is applied, has shown higher clearance than PDT alone in several studies. Non-ablative lasers and intense pulsed light, the standard tools for brown spots and redness covered in the pieces on laser versus chemical peel and facial redness and vascular lasers, are not reliable AK treatments. A patient whose IPL package was sold as "treating the sun damage" may leave with fewer brown spots and every rough patch intact.

So resurfacing can count as treatment. The problem is what it erases. A laser vaporizes the lesion and sends nothing to a lab. That is fine for a typical thin AK that a dermatologist has examined and recognized. It is not fine for a lesion that is thick, tender, growing, bleeding, ulcerated, or not behaving like its neighbors. Those features raise the possibility of invasive SCC, which needs a biopsy and then excision or Mohs surgery, not a pass with a laser that removes the visible part and leaves cancer cells deeper in the skin. Lasering a lentigo maligna that was mistaken for a sun spot carries the same risk, with the added problem that the pigment cleared from the surface can mask a recurrence for years.

The same principle runs through the earlier pieces on cosmetic mole removal, seborrheic keratoses and other benign growths, and pathology reports after cosmetic surgery: if there is any doubt about what something is, the tissue goes to a pathologist before it is destroyed. Many good resurfacing practices build in a dermatology skin check before treatment, mark any suspicious lesion, and biopsy it first. A practice that does not, particularly one where the treating provider is not a physician, is relying on luck. The piece on who is injecting you at a med spa explains why supervision matters most at moments like this one.

"

A laser can treat actinic keratoses well. What it cannot do is tell you what it just removed. The biopsy has to come first, because once the lesion is vaporized, the only diagnosis left is the one nobody made.

"

Timing around facelifts, injectables, and the lower lip

The short answer: finish field treatment and let the skin fully settle, usually several weeks, before facial surgery, resurfacing, or injections in the treated area, and treat the sun-damaged lower lip, called actinic cheilitis, before augmenting it.

Facial surgery and AK treatment do not conflict in principle, but they compete for the same skin. A face that is raw and crusted from 5-FU or imiquimod is inflamed, colonized with more bacteria than usual, and less able to tolerate incisions near the hairline and ears. Most surgeons prefer that a field treatment be completed and the skin fully healed, typically four to six weeks after the last application, before a mini facelift or a deep plane facelift. Doing the field treatment first also gives the dermatologist a cleaner, calmer field to examine, and it gives the surgeon an honest picture of the skin quality they are about to redrape.

Some patients prefer to combine the jobs: a facelift, then ablative resurfacing of the face months later as both a cosmetic and medical treatment. That is a reasonable plan if the resurfacing is deep enough to count, the face has been checked for suspicious lesions first, and the gap after surgery is long enough that the lifted skin has recovered its blood supply. The piece on skin necrosis after facelift and tummy tuck explains why aggressive treatment of freshly lifted skin is risky, and surgeons set their own waiting periods accordingly.

Injectables follow a simpler rule: do not inject filler or neurotoxin into skin that is actively inflamed from a field therapy, and wait until it has fully recovered. Planning a 5-FU course in the month before a wedding or a major event is a predictable mistake; the timing principles in the piece on injectables before a big event apply to AK treatment too. Patients with a history of cold sores should also know that any treatment that inflames the skin around the mouth, including 5-FU, imiquimod, PDT, peels, and lasers, can trigger a flare, and antiviral prophylaxis is often used, as described in the piece on HSV reactivation after cosmetic procedures.

The lower lip deserves its own attention. Actinic cheilitis is the AK equivalent on the lip: a dry, scaly, whitish or blotchy lower lip in which the sharp border between the red lip and the surrounding skin becomes blurred. It is common in people with heavy outdoor exposure, and SCC of the lip can arise from it. A patient asking for lip filler, a surgical lip lift, or treatment of smoker's lines around the mouth who has a chronically scaly lower lip should have it evaluated first. Treatment options include topical field creams, PDT, ablative laser vermilion resurfacing, and, for more severe cases, surgical removal of the damaged lip surface (vermilionectomy). Filling a lip before addressing actinic cheilitis makes it harder to examine, and a persistent sore or thickened area on the lip should be biopsied, never just plumped.

The scalp and hands complete the map. Patients with thinning hair or in a hairline lowering or hair transplant consultation often carry AKs across the scalp that were never visible under hair; the same is true of the backs of the hands in people asking about hand rejuvenation and the upper chest in decolletage rejuvenation. A cosmetic consultation for any sun-exposed area is a natural moment for a skin check.

Prevention that has evidence: sunscreen, nicotinamide, and the medicine cabinet

The short answer: daily broad-spectrum sunscreen reduces new AKs and squamous cell carcinoma, oral nicotinamide modestly reduces new skin cancers in high-risk people while it is being taken, and some common medications increase sun sensitivity and deserve a review.

Sunscreen is the one prevention measure with randomized evidence behind it. An Australian trial published in the New England Journal of Medicine in 1993 found that daily sunscreen use over a single summer reduced new AKs and increased regression of existing ones. A larger community trial in Nambour, Queensland, found that regular daily sunscreen use reduced the incidence of SCC over several years. The AAD recommends broad-spectrum SPF 30 or higher, reapplied during outdoor activity, along with hats and shade. For cosmetic patients, this is not a separate instruction from the post-procedure advice in the piece on scar care after plastic surgery. It is the same habit, and it protects both the result and the skin.

Nicotinamide, a form of vitamin B3, has the most interesting supplement evidence in this area. The ONTRAC trial, published in the New England Journal of Medicine in 2015, randomized people with at least two prior nonmelanoma skin cancers to 500 milligrams of nicotinamide twice daily or placebo for a year. The nicotinamide group had about 23 percent fewer new nonmelanoma skin cancers and modestly fewer AKs. The benefit disappeared after stopping. A later trial in organ transplant recipients, published in 2023, did not show a significant benefit, so the evidence is strongest for immunocompetent high-risk patients. Nicotinamide is not the same as niacin, which causes flushing and can affect the liver at high doses, and anyone considering it should confirm the exact product with a dermatologist. Patients reviewing their supplement stop list before surgery should mention it, though it is not a bleeding concern.

The medicine cabinet matters too. Several common drugs make skin more sensitive to sunlight, including some antibiotics (doxycycline), the antifungal voriconazole, and the blood pressure diuretic hydrochlorothiazide. In 2020, the FDA approved label changes for hydrochlorothiazide noting an increased risk of nonmelanoma skin cancer, particularly with long-term use, based largely on Danish population studies. Nobody should stop a blood pressure medication on their own; the reasons are covered in the piece on high blood pressure before cosmetic surgery. But a patient with many AKs who takes hydrochlorothiazide may reasonably ask their doctor whether an alternative makes sense. Topical retinoids, which many cosmetic patients already use, improve photoaging, but a large Veterans Affairs trial found that high-strength topical tretinoin did not prevent keratinocyte carcinomas; patients should not count on their retinoid as AK prevention. And anyone who has recently taken oral isotretinoin should check the timing guidance in the piece on isotretinoin waiting periods before procedures before resurfacing.

The long view is surveillance. A person with many AKs or a prior SCC benefits from regular full skin examinations, usually once or twice a year, and from learning what a new, growing, or tender spot feels like. Repeated field treatments every few years are common and expected. The skin does not get a one-time cure; it gets managed.

The honest summary

Actinic keratoses are the rough, scaly, often invisible-until-touched patches that mark sun-damaged skin. Each one is unlikely to become cancer, but together they identify a field of skin where squamous cell carcinoma is more likely, and treating that field reduces future cancers. Isolated spots are usually frozen. Areas with many spots are usually treated with fluorouracil, imiquimod, tirbanibulin, or photodynamic therapy, each of which causes a planned, temporary reaction that patients can schedule around.

Cosmetic resurfacing overlaps with this treatment more than many patients realize. Ablative lasers and medium-depth or deep peels can clear many AKs and may reduce future skin cancers. Intense pulsed light and most non-ablative lasers do not reliably treat them, regardless of how a package is marketed. And no laser can provide a diagnosis: any lesion that is thick, tender, growing, bleeding, or different from its neighbors needs a biopsy before it is destroyed, as does any brown spot that looks unusual.

Timing is straightforward once the skin is treated as skin and not as a backdrop. Finish field therapy and allow the face to settle for several weeks before a facelift, resurfacing, or injections. Have a scaly lower lip examined before filler or a lip lift. Use daily sunscreen, consider nicotinamide if a dermatologist agrees that the risk profile fits, and review medications that increase sun sensitivity.

The patient at the top of this piece saw a dermatologist before the laser appointment. Eleven rough patches were confirmed as AKs, and one thick, tender spot at the right temple was biopsied and turned out to be an early squamous cell carcinoma, which was excised. The rest of the field was treated with a four-week course of fluorouracil in midwinter, which was unpleasant for about ten days and then resolved. The brown spots were treated afterward with a pigment laser, and the facelift went ahead in spring on calmer, checked skin. The cosmetic plan did not change much. The order did, and that made the difference.